Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12511006 | 1.00 | MGAM (0.33) | MGAMCA1CA2GAASI | |
| SCHEMBL13825725 | 1.00 | MGAM (0.33) | MGAMCA1CA2GAASI | |
| SCHEMBL13825710 | 1.00 | MGAM (0.33) | MGAMCA1CA2GAASI | |
| SCHEMBL10099996 | 1.00 | MGAM (0.33) | MGAMCA1CA2GAASI | |
| SCHEMBL10099994 | 0.84 | MGAM (0.31) | MGAMCA1CA2GAASI | |
| SCHEMBL10063783 | 0.84 | MGAM (0.35) | MGAMCA1CA2GAASI | |
| SCHEMBL20401977 | 0.82 | — | — | |
| SCHEMBL17466776 | 0.82 | MGAM (0.34) | MGAMCA1CA2GAASI | |
| SCHEMBL25468150 | 0.79 | — | — | |
| SCHEMBL23640700 | 0.77 | MGAM (0.30) | MGAMCA1CA2GAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7982060-B2 | Intermediates for the preparation of analogs of Halichondrin B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-07-19 | — | — | US | disclosed |
| US-20070244187-A1 | Intermediates for the Preparation of Halichondrin B | EISAI CO., LTD (JP) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244187-A1 | Intermediates for the Preparation of Halichondrin B | CDK4, CCNB1, CDK14 | MGAM 4853/4885CA1 3967/4885CA2 3356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.